Literature DB >> 11033441

Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice.

S Mohan1, S Kutilek, C Zhang, H G Shen, Y Kodama, A K Srivastava, J E Wergedal, W G Beamer, D J Baylink.   

Abstract

In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs. Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation. PTH(2-34) was much less potent, whereas PTH(1-31) was equipotent in stimulating bone formation parameters in mice. PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent. Because PTH(1-31) caused a smaller increase in bone resorption parameters compared to PTH(1-34), despite similar effects on bone formation parameters, we evaluated the long-term anabolic effects of PTH(1-31) and PTH(1-34) in mice. Weekly evaluations of serum osteocalcin levels demonstrated that daily injections of PTH(1-34) and PTH(1-31) at 80 microg/kg body weight increased serum osteocalcin levels within 1 week of the start of treatment, which were maintained during the entire 22 week treatment. Assessment of bone density at the end of the treatment period with peripheral quantitated computed tomography (pQCT) revealed that PTH(1-34) caused a significantly greater increase in femoral bone density compared to PTH(1-31) at the middiaphysis (18% vs. 9% over vehicle control; p < 0.001). Both PTH(1-34) and PTH(1-31) increased periosteal circumference compared to vehicle (p < 0.01) without a significant difference between the two treatments. In contrast, PTH(1-34) caused a significantly greater reduction in endosteal circumference than PTH(1-31) (p < 0.001). Both analogs significantly increased maximum load and area of moment of inertia over the vehicle group. In conclusion, our findings suggest that PTH(1-34) and PTH(1-31) may exhibit different anabolic effects at the periosteum vs. endosteum in the long bones of mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033441     DOI: 10.1016/s8756-3282(00)00355-0

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.

Authors:  Subburaman Mohan; Charmaine Richman; Rongqing Guo; Yousef Amaar; Leah Rea Donahue; Jon Wergedal; David J Baylink
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

Review 2.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

3.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 4.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

Review 5.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 6.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

7.  Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow.

Authors:  Christian E Jacome-Galarza; Sun-Kyeong Lee; Joseph A Lorenzo; Hector Leonardo Aguila
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

8.  Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation.

Authors:  Gabriel R Linares; Robert Brommage; David R Powell; Weirong Xing; Shin-Tai Chen; Fatima Z Alshbool; K-H William Lau; Jon E Wergedal; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

9.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Authors:  Diane Gesty-Palmer; Ling Yuan; Bronwen Martin; William H Wood; Mi-Hye Lee; Michael G Janech; Lam C Tsoi; W Jim Zheng; Louis M Luttrell; Stuart Maudsley
Journal:  Mol Endocrinol       Date:  2013-01-11

10.  Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice.

Authors:  Yuji Kasukawa; David J Baylink; Rongqing Guo; Subburaman Mohan
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.